1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

What does Actavis get in $66bn Allergan buy?

 
• By Mandy Jackson

When Actavis closes its $66bn acquisition of Allergan, the generic drug specialist and growing brand-name medicine marketer will grow in international markets and strengthen or add products in certain disease areas (scripintelligence.com, 18 November 2014).

When Actavis closes its $66bn acquisition of Allergan, the generic drug specialist and growing brand-name medicine marketer will grow in international markets and strengthen or add products in certain disease areas (scripintelligence.com, 18 November 2014).

Actavis will expand its international business base in Canada, Europe, Southeast Asia and other emerging markets, such as China, India,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

Direct-To-Consumer And Lower Prices Key To Novo Nordisk’s Wegovy Fightback

 
• By Andrew McConaghie

The company’s incoming CEO Mike Doustdar has promised greater agility, competitiveness and execution, but investors are yet to be convinced.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

 
• By Alaric DeArment

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 
• By Andrew McConaghie

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.

More from Therapy Areas

Novartis’s ‘Pipeline-In-A-Product’ Assets Progressing Well

 
• By Kevin Grogan

CMO Shreeram Aradhye talks to Scrip about the promise shown by ianalumab, remibrutinib and a next-generation CAR-T for immunological disorders.

Vertex’s Pain Drug Failure Adds To Investor Doubts

 
• By Andrew McConaghie

A Phase II trial to develop a second NaV1.8 pain signal inhibitor for acute pain has failed and the US FDA has given a thumbs down on Journavx’s path to broader use in peripheral neuropathic pain.

Cardiff Pushes Towards Colorectal Cancer Phase III As Funding Questions Loom

 
• By Manas Mishra

Cardiff Oncology is open to going it alone, a partnership and even an exit as the San Diego, CA-based firm tries to push its PLK1 inhibitor through late-stage development.